Literature DB >> 7897204

Heat-inactivated Sendai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo.

T Liu1, X Zhou, C Orvell, E Lederer, H G Ljunggren, M Jondal.   

Abstract

We have earlier described an alternative MHC class I processing pathway for Sendai virus (SV) in H-2Kb-transfected T2 cells (T2Kb). These cells have deleted genes for transporters associated with Ag processing (TAP1/2) and proteasome subunits LMP2/7 but can still process SV for the presentation of an immunodominant nucleoprotein CTL epitope (nucleoprotein peptide 324-332, FAPGNYPAL, SV9), even in the presence of the fungal metabolite brefeldin A (BFA). Presently we have compared live and heat-inactivated SV to investigate whether infectious virus, including early events such as binding and fusion at the host cell membrane, is important for nonclassical MHC class I processing and immunogenicity. We have found that heated virus (56 degrees C, boiled or autoclaved) with no fusion and hemagglutinin-neuraminidase activities, behaves similar to live SV in T2kb cells by entering a TAP-independent and BFA-resistant pathway. In EL-4 cells, which do not express this nonclassical TAP-independent and BFA-resistant pathway, heat-treated SV is processed in a BFA-sensitive way. In T1Kb- and TAP1/2-transfected T2Kb cells, as in T2Kb cells, processing of heat-inactivated SV was completely BFA resistant. Heat-inactivated SV was also found to prime CTLs in vivo. We conclude that heat-inactivated SV can enter both BFA-sensitive and -resistant MHC class I processing pathways and that SV in this respect may be particularly efficient. What property in the SV that is important for this characteristic is presently not clear but might be useful for the deliberate generation of CTL responses in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7897204

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  Class I MHC presentation of exogenous antigens.

Authors:  C V Harding
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

2.  Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein.

Authors:  H L Van Epps; C S Schmaljohn; F A Ennis
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

3.  Peptide-receptive class I major histocompatibility complex molecules on TAP-deficient and wild-type cells and their roles in the processing of exogenous antigens.

Authors:  R Song; A Porgador; C V Harding
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

4.  Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.

Authors:  K Grovit-Ferbas; J F Hsu; J Ferbas; V Gudeman; I S Chen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars.

Authors:  M N Starnbach; M J Bevan; M F Lampe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

6.  Virus-specific antigen presentation by different subsets of cells from lung and mediastinal lymph node tissues of influenza virus-infected mice.

Authors:  A Hamilton-Easton; M Eichelberger
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells.

Authors:  Victoria A Pudney; Alison M Leese; Alan B Rickinson; Andrew D Hislop
Journal:  J Exp Med       Date:  2005-01-31       Impact factor: 14.307

8.  CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

Authors:  Gabriel Morón; Paloma Rueda; Ignacio Casal; Claude Leclerc
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.